Quest Diagnostics Toekomstige groei
Future criteriumcontroles 1/6
Quest Diagnostics zal naar verwachting groeien in winst en omzet met respectievelijk 11.7% en 4.9% per jaar. De winst per aandeel zal naar verwachting groeien met 11.1% per jaar. Het rendement op het eigen vermogen zal over 3 jaar naar verwachting 15.5% zijn.
Belangrijke informatie
11.7%
Groei van de winst
11.1%
Groei van de winst per aandeel
Healthcare winstgroei | 20.8% |
Inkomstengroei | 4.9% |
Toekomstig rendement op eigen vermogen | 15.5% |
Dekking van analisten | Good |
Laatst bijgewerkt | 18 Nov 2024 |
Recente toekomstige groei-updates
Earnings Update: Quest Diagnostics Incorporated (NYSE:DGX) Just Reported Its Third-Quarter Results And Analysts Are Updating Their Forecasts
Oct 25Results: Quest Diagnostics Incorporated Beat Earnings Expectations And Analysts Now Have New Forecasts
Apr 26Recent updates
Investors Met With Slowing Returns on Capital At Quest Diagnostics (NYSE:DGX)
Nov 12Earnings Update: Quest Diagnostics Incorporated (NYSE:DGX) Just Reported Its Third-Quarter Results And Analysts Are Updating Their Forecasts
Oct 25Quest Diagnostics: Organic Growth Leads To Q3 Earnings Beat
Oct 24Why Investors Shouldn't Be Surprised By Quest Diagnostics Incorporated's (NYSE:DGX) P/E
Oct 23Quest Diagnostics: The Better Half Of An Emerging Healthcare Duopoly
Oct 15These 4 Measures Indicate That Quest Diagnostics (NYSE:DGX) Is Using Debt Reasonably Well
Aug 30Should You Think About Buying Quest Diagnostics Incorporated (NYSE:DGX) Now?
Aug 12Quest Diagnostics: Beat Down After Beating Q2 Estimates
Jul 28The Price Is Right For Quest Diagnostics Incorporated (NYSE:DGX)
Jul 12Quest Diagnostics: On A Quest For Growth
Jul 12Quest Diagnostics (NYSE:DGX) Hasn't Managed To Accelerate Its Returns
May 14Quest Diagnostics: Let's Keep Waiting
May 08Results: Quest Diagnostics Incorporated Beat Earnings Expectations And Analysts Now Have New Forecasts
Apr 26We Think Quest Diagnostics (NYSE:DGX) Can Stay On Top Of Its Debt
Apr 23Unpleasant Surprises Could Be In Store For Quest Diagnostics Incorporated's (NYSE:DGX) Shares
Apr 02Quest Diagnostics (NYSE:DGX) Is Paying Out A Larger Dividend Than Last Year
Mar 15Quest Diagnostics (NYSE:DGX) Has Announced That It Will Be Increasing Its Dividend To $0.75
Feb 06Quest Diagnostics: Post-COVID Normalization Pretty Much Done
Feb 05Quest Diagnostics (NYSE:DGX) Seems To Use Debt Quite Sensibly
Jan 11Why We're Not Concerned About Quest Diagnostics Incorporated's (NYSE:DGX) Share Price
Dec 24Quest Diagnostics: Market Overreaction Creates Investment Opportunity
Dec 08Is There Now An Opportunity In Quest Diagnostics Incorporated (NYSE:DGX)?
Dec 06Quest Diagnostics' (NYSE:DGX) Returns Have Hit A Wall
Nov 18Quest Diagnostics: Moving Past Covid
Oct 25Here's Why Quest Diagnostics (NYSE:DGX) Can Manage Its Debt Responsibly
Sep 25What Does Quest Diagnostics Incorporated's (NYSE:DGX) Share Price Indicate?
Sep 04Quest Diagnostics: Q2 Earnings Reveal Promising Growth Trends Despite Dwindling COVID Testing Revenues
Aug 15Quest Diagnostics (NYSE:DGX) Has More To Do To Multiply In Value Going Forward
Aug 13Quest Diagnostics Incorporated (NYSE:DGX) Shares Could Be 46% Below Their Intrinsic Value Estimate
Jul 11Is Quest Diagnostics (NYSE:DGX) A Risky Investment?
Jun 09Quest Diagnostics: Healthier Diagnosis
May 30Is It Time To Consider Buying Quest Diagnostics Incorporated (NYSE:DGX)?
May 24Quest Diagnostics (NYSE:DGX) Has More To Do To Multiply In Value Going Forward
May 09An Intrinsic Calculation For Quest Diagnostics Incorporated (NYSE:DGX) Suggests It's 24% Undervalued
Mar 22What Does Quest Diagnostics Incorporated's (NYSE:DGX) Share Price Indicate?
Feb 19Winst- en omzetgroeiprognoses
Datum | Inkomsten | Inkomsten | Vrije kasstroom | Geldmiddelen uit operationele activiteiten | Gem. Aantal analisten |
---|---|---|---|---|---|
12/31/2026 | 11,003 | 1,089 | 1,330 | 1,760 | 13 |
12/31/2025 | 10,635 | 1,001 | 1,090 | 1,494 | 16 |
12/31/2024 | 9,833 | 906 | 915 | 1,305 | 13 |
9/30/2024 | 9,539 | 838 | 1,023 | 1,397 | N/A |
6/30/2024 | 9,346 | 836 | 875 | 1,248 | N/A |
3/31/2024 | 9,287 | 842 | 947 | 1,332 | N/A |
12/31/2023 | 9,252 | 850 | 864 | 1,272 | N/A |
9/30/2023 | 9,297 | 759 | 596 | 1,079 | N/A |
6/30/2023 | 9,488 | 790 | 878 | 1,374 | N/A |
3/31/2023 | 9,603 | 789 | 864 | 1,332 | N/A |
12/31/2022 | 9,883 | 942 | 1,314 | 1,718 | N/A |
9/30/2022 | 10,294 | 1,230 | 1,464 | 1,865 | N/A |
6/30/2022 | 10,582 | 1,479 | 1,552 | 1,924 | N/A |
3/31/2022 | 10,679 | 1,874 | 1,602 | 1,982 | N/A |
12/31/2021 | 10,788 | 1,988 | 1,830 | 2,233 | N/A |
9/30/2021 | 11,046 | 2,175 | 1,872 | 2,293 | N/A |
6/30/2021 | 11,058 | 2,238 | 2,171 | 2,594 | N/A |
3/31/2021 | 10,335 | 1,794 | 2,068 | 2,489 | N/A |
12/31/2020 | 9,437 | 1,425 | 1,587 | 2,005 | N/A |
9/30/2020 | 8,361 | 1,101 | 1,384 | 1,812 | N/A |
6/30/2020 | 7,531 | 749 | 816 | 1,249 | N/A |
3/31/2020 | 7,657 | 771 | 779 | 1,215 | N/A |
12/31/2019 | 7,726 | 835 | 843 | 1,243 | N/A |
9/30/2019 | 7,639 | 709 | 811 | 1,190 | N/A |
6/30/2019 | 7,572 | 707 | 929 | 1,293 | N/A |
3/31/2019 | 7,538 | 720 | 938 | 1,295 | N/A |
12/31/2018 | 7,531 | 733 | 817 | 1,200 | N/A |
9/30/2018 | 7,557 | 860 | 914 | 1,228 | N/A |
6/30/2018 | 7,524 | 808 | N/A | 1,188 | N/A |
3/31/2018 | 7,469 | 782 | N/A | 1,159 | N/A |
12/31/2017 | 7,402 | 769 | N/A | 1,175 | N/A |
9/30/2017 | 7,398 | 671 | N/A | 1,156 | N/A |
6/30/2017 | 7,427 | 701 | N/A | 1,095 | N/A |
3/31/2017 | 7,469 | 702 | N/A | 1,112 | N/A |
12/31/2016 | 7,214 | 642 | N/A | 1,116 | N/A |
9/30/2016 | 7,503 | 675 | N/A | 1,037 | N/A |
6/30/2016 | 7,498 | 825 | N/A | 948 | N/A |
3/31/2016 | 7,517 | 748 | N/A | 922 | N/A |
12/31/2015 | 7,493 | 706 | N/A | 821 | N/A |
9/30/2015 | 7,527 | 703 | N/A | 852 | N/A |
6/30/2015 | 7,551 | 491 | N/A | 911 | N/A |
3/31/2015 | 7,528 | 507 | N/A | 906 | N/A |
12/31/2014 | 7,435 | 549 | N/A | 944 | N/A |
9/30/2014 | 7,308 | 506 | N/A | 845 | N/A |
6/30/2014 | 7,192 | 780 | N/A | 761 | N/A |
3/31/2014 | 7,105 | 799 | N/A | 689 | N/A |
12/31/2013 | 7,146 | 811 | N/A | 652 | N/A |
Toekomstige groeivoorspellingen analisten
Verdiensten versus spaarpercentage: De verwachte winstgroei DGX ( 11.7% per jaar) ligt boven de spaarquote ( 2.6% ).
Winst versus markt: De winst van DGX ( 11.7% per jaar) zal naar verwachting langzamer groeien dan de markt US ( 15.4% per jaar).
Hoge groeiwinsten: De winst van DGX zal naar verwachting groeien, maar niet aanzienlijk.
Omzet versus markt: De omzet van DGX ( 4.9% per jaar) zal naar verwachting langzamer groeien dan de markt US ( 9% per jaar).
Hoge groei-inkomsten: De omzet van DGX ( 4.9% per jaar) zal naar verwachting langzamer groeien dan 20% per jaar.
Groeiprognoses winst per aandeel
Toekomstig rendement op eigen vermogen
Toekomstige ROE: Het rendement op eigen vermogen DGX zal naar verwachting over 3 jaar laag zijn ( 15.5 %).